Core Insights - Firefly Neuroscience, Inc. is collaborating with Heidelberg University Hospital to study the neurophysiological impact of 15q13.3 copy number variants (CNVs) [1][3] - The study utilizes Firefly's FDA-cleared technology to analyze EEG data from 30 subjects, aiming to uncover insights into brain function related to rare genetic conditions [2][3] - The collaboration reflects a commitment to advancing precision neuroscience and aims to bridge the gap between genotype and phenotype for better patient care [3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with a proprietary technology called Brain Network Analytics (BNA™) [7][8] - The company has built a comprehensive database of brain wave tests over the past 15 years and has achieved FDA clearance for its technology [7][8] - Firefly is targeting pharmaceutical companies and medical practitioners for the commercial launch of its BNA™ technology [7] Study Objectives - The study aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs [6] - It will characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region [6] - The research supports future diagnostic and therapeutic strategies for neurodevelopmental disorders [6]
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research